A Republican bill with 6 Democratic cosponsors · See all 13 cosponsors
Last activity — Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.
Cleared committee, waiting for its first floor vote
A committee approved it and it is on the calendar of the chamber it started in.
This is further than most bills get, and still no promise of a vote: the calendar is a queue, and the majority leadership decides what is called. A bill can sit here until the Congress ends.
Its path through Congress
- Introduced
- On Calendar
What this bill would do
The Prescription Pricing for the People Act of 2025 requires the Federal Trade Commission to conduct a study on the role of intermediaries in the pharmaceutical supply chain. The Commission must investigate specific practices of pharmacy benefit managers, such as pricing discrepancies, patient steering, and the use of proprietary data. The study also looks at competition trends and the costs or risks associated with contracting with intermediaries. Additionally, the Commission is tasked with identifying legal or regulatory obstacles that affect drug prices or antitrust enforcement. Finally, the Act mandates that the Commission provide policy or legislative recommendations to improve transparency and competition.
Yes· 3 of 5
- Scored +5
Does this give people more protection from unfair business practices?
The bill directs the FTC to investigate anticompetitive practices and provide recommendations to better protect consumers in the drug market.
- Scored +5
Does this lower the price of prescription medicines?
The act tasks the FTC with identifying regulatory obstacles that contribute to high drug prices and investigating practices of pharmacy benefit managers that may inflate costs.
- Scored +4
Does this make what the government does easier for the public to see?
The bill seeks to increase information availability to consumers and payers regarding the roles of pharmaceutical intermediaries.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Improved Transparency and Competition: The bill requires the Commission to provide policy or legislative recommendations intended to improve transparency and competition in the pharmaceutical supply chain (Section 3(a)(2)(C)(i)).
-
Prevention of Unfair Business Practices: The Act seeks recommendations to prevent and deter anticompetitive behavior within the pharmaceutical supply chain (Section 3(a)(2)(C)(ii)).
-
Consumer Benefits from Market Changes: The study aims to find ways to ensure consumers benefit from cost savings or efficiencies that might result from mergers and consolidations (Section 3(a)(2)(C)(iii)).
-
Addressing Drug Pricing Obstacles: The Commission is directed to look into whether specific legal or regulatory obstacles contribute to the cost of prescription drug prices (Section 3(a)(1)(E)).
Potential Negative Impacts for People
- No specific negative impacts are explicitly mentioned in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would households on low incomes be better off under this? — By investigating ways to reduce prescription drug costs, the bill could potentially lower the financial burden on low-income households. Would middle-income households be better off under this? — Lowering prescription drug prices through increased competition may benefit middle-class households' spending power.
- Economy And Finance
- Does this give people more protection from unfair business practices? — The bill directs the FTC to investigate anticompetitive practices and provide recommendations to better protect consumers in the drug market.
- Healthcare
- Does this lower the price of prescription medicines? — The act tasks the FTC with identifying regulatory obstacles that contribute to high drug prices and investigating practices of pharmacy benefit managers that may inflate costs.
- Governance And Ideology
- Does this make what the government does easier for the public to see? — The bill seeks to increase information availability to consumers and payers regarding the roles of pharmaceutical intermediaries.
- 7/9/2025
- 1 Cosponsor added.
- 4/10/2025
- Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
- Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.
- 4/7/2025
- 1 Cosponsor added.
- 4/3/2025
- Committee on the Judiciary. Ordered to be reported without amendment favorably.
- 4/2/2025
- 1 Cosponsor added.
- 2/11/2025
- Read twice and referred to the Committee on the Judiciary.
- 10 Cosponsors added.
- Introduced in Senate
John BoozmanRepublican · Arkansas
Marsha BlackburnRepublican · Tennessee
Richard BlumenthalDemocrat · Connecticut
Maria CantwellDemocrat · Washington
Shelley CapitoRepublican · West Virginia
Christopher CoonsDemocrat · Delaware
Mazie HironoDemocrat · Hawaii
James LankfordRepublican · Oklahoma
Roger MarshallRepublican · Kansas
Tommy TubervilleRepublican · Alabama
Thomas TillisRepublican · North Carolina
Raphael WarnockDemocrat · Georgia
Peter WelchDemocrat · Vermont